Comparative study of biological characteristics between paediatric hepatocellular tumors and adult hepatocellular carcinoma

Paper Details

Research Paper 10/12/2024
Views (771)
current_issue_feature_image
publication_file

Comparative study of biological characteristics between paediatric hepatocellular tumors and adult hepatocellular carcinoma

Kosuke Kudo, Juma Obayashi, Koji Fukumoto, Hiroaki Kitagawa, Shigeyuki Furuta, Junki Koike
Int. J. Biomol. Biomed. 19(3), 1-5, December 2024.
Copyright Statement: Copyright 2024; The Author(s).
License: CC BY-NC 4.0

Abstract

The biological differences between paediatric hepatocytic tumours (pHCT) and adult hepatocellular carcinoma (aHCC) remain unclear. This study aimed to compare the expression of hepatocyte-specific proteins, liver stem cell markers, and sinusoidal endothelial cell proteins in pHCTs and aHCCs using immunohistochemistry. A retrospective analysis identified 31 cases of pHCTs (24 hepatoblastomas and 7 paediatric hepatocellular carcinomas) treated at our hospital and other hospitals, where tumour biopsy or liver resection was performed. Pathological features were compared with 36 cases of aHCC. Tumour markers, including Hep Par-1, Arginase1, Glypican3 (GPC3), AFP, CD56, C-kit, and CD34, were examined. GPC3 was expressed in all pHCTs except for one hepatoblastoma case, while it was detected in only 18/36 aHCC cases, particularly those without chronic liver disease in adjacent tissue. HepPar-1 was expressed in all paediatric and adult tumours except for one pHCT case, and Arginase1 and AFP were universally expressed. CD56 and c-kit were not identified in any tumours, and CD4 expression was absent in sinusoidal microvascular endothelial cells, but CD34 was consistently expressed in all cases. These findings reveal significant biological differences between pHCC and aHCC, highlighting GPC3 as a potential characteristic marker of paediatric hepatocytic tumours.

Cottereau E, Mortemousque I, Moizard M, Bürglen L, Lacombe D, Gilbert-Dussardier B, Sigaudy S, Boute O, David A, Faivre L, Amiel J, Robertson R, Ramos FV, Bieth E, Odent S, Demeer B, Mathieu M, Gaillard D, Van Maldergem L, Baujat G, Maystadt I, Héron D, Verloes A, Philip N, Cormier-Daire V, Frouté MF, Pinson L, Blanchet P, Sarda P, Willems M, Jacquinet A, Ratbi I, van den Ende J, Lackmy-Port Lis M, Goldenberg A, Bonneau D, Rossignol S, Toutain A. 2013. Phenotypic spectrum of Simpson-Golabi-Behmel syndrome in a series of 42 cases with a mutation in GPC3 and review of the literature. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 163C, 92–105. DOI: 10.1002/ajmg.c.31360

Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joffé EB. 2008. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histology and Histopathology 23, 1333–1340.

Kinoshita Y, Tanaka S, Souzaki R, Miyoshi K, Kohashi K, Oda Y, Nakatsura T, Taguchi T. 2015. Glypican 3 expression in pediatric malignant solid tumors. European Journal of Pediatric Surgery 25, 138–144. DOI: 10.1055/s-0034-1393961.

Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. 2003. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochemical and Biophysical Research Communications 306, 16–25. DOI: 10.1016/S0006-291X(03)00908-2.

Tsuchiya N, Hosono A, Yoshikawa T, Shoda K, Nosaka K, Shimomura M, Hara J, Nitani C, Manabe A, Yoshihara H, Hosoya Y, Kaneda H, Kinoshita Y, Kohashi K, Yoshimura K, Fujinami N, Saito K, Mizuno S, Nakatsura T. 2018. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. OncoImmunology 7(1), e1377872. DOI: 10.1080/2162402X.2017.1377872.

Zynger DL, Gupta A, Luan C, Chou PM, Yang GY, Yang XJ. 2008. Expression of glypican 3 in hepatoblastoma: An immunohistochemical study of 65 cases. Human Pathology 39(2), 224–230. DOI: 10.1016/j.humpath.2007.06.006.

Related Articles

Evaluation of antibody to double stranded DNA and antibody to single stranded DNA levels in relation to biochemical markers in cardiovascular disease patients

Cyrille A. Vodounon, Lilya A. Ganeeva, Sergey N. Abramov, Atindehou G. Dossou, Boris B. Legba, Yulia Valerevna skibo, Zinaida I. Abramova, Int. J. Biomol. Biomed. 20(2), 1-9, April 2025.

Food preference and inflammation: How taste shapes health

Dramane Gado, Lagaki Abdel Koudousse, Kenoukon Camaëlle, Natta Rodolpho, Houndonougbo Antoine, Yadouleton Anges, Yessoufou Akadiri, Int. J. Biomol. Biomed. 20(1), 1-10, February 2025.

Feeding management on the growth and survival rate of mud crab (Scylla serrata)

Paňares Gesila Grace Prieto, Daisy T. Genosas, Ivy Mae T. Moquiala, Lorena J. Jumawan, Grilly P. Persigas, Rachel V. Baclay, Huberto O. Origenes, Maria Danesa S. Rabia, Int. J. Biomol. Biomed. 19(1), 1-5, August 2024.

Controlled production trials of conôro, A natural condiment

Konan Sylvestre Kongoza, Wahauwouélé Hermann Coulibaly, Yves Djina, Tia Jean Gonnety , Meuwiah Betty Faulet , Int. J. Biomol. Biomed. 18(3), 1-10, June 2024.

Exploring pharmacologically significant bioactive compounds of Psoralea corylifolia L.- A review

G. Bhagirath, G. Surendra Reddy, M. D. Mustafa, Int. J. Biomol. Biomed. 18(2), 11-18, April 2024.

Seasonal impact on physico-chemical parameters of fresh water resources- A review

M. Manonmani, TA. Sathya, R. Anburaj, K. Gokilavani, PS. Geethanjali4, S. Viswanathan, Int. J. Biomol. Biomed. 18(2), 1-10, April 2024.

Evaluation of antioxidant activity of lime juice extract of cashew bark in normal and wistar rats with indomethacin toxicity

Godwin Anyim, Morakinyo Adetoun Elizabeth, Babarinde Samuel Olufolarin, Bamgboye Faith Funke, Akinbinu Ibukunoluwa Rebecca, Oyedemi Temitope, Oyedepo Temitope Adenike, Int. J. Biomol. Biomed. 18(1), 26-37, February 2024.